Skip to main content
main-content

Respiratory

Respiratory

29-04-2021 | Oncology | News | Article

Nivolumab–ipilimumab receives nod from EMA for malignant pleural mesothelioma

Click through to read more details

27-04-2021 | Oncology | News | Article

KEYNOTE-158 points to pembrolizumab potential in advanced mesothelioma

Pembrolizumab monotherapy can achieve responses lasting for more than a year in some patients with previously treated malignant pleural mesothelioma (MPM), suggest phase 2 trial data.

26-04-2021 | Oncology | News | Article

EMA recommends extending osimertinib indication

Find out more about this decision here

20-04-2021 | Oncology | News | Article

Retreatment with tremelimumab–durvalumab feasible in mesothelioma patients

The NIBIT-MESO-1 trial suggests that retreatment with tremelimumab plus durvalumab could be a viable option for patients with unresectable mesothelioma who progress after initially benefiting from the combination.

19-04-2021 | Oncology | News | Article

Chemoimmunotherapy may be preferable for KRAS wild-type NSCLC

Chemoimmunotherapy may be a better option than immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer patients with high PD-L1 expression and no KRAS mutations, indicate findings.

16-04-2021 | Oncology | News | Article

ESMO issues recommendations for SCLC management

More information on these Clinical Practice Guidelines available here

15-04-2021 | Oncology | News | Article

Sintilimab could be a viable second-line option for advanced squamous NSCLC

Patients with advanced squamous non-small-cell lung cancer derive a significant overall survival benefit from second-line treatment with sintilimab versus docetaxel, suggest results from the Chinese ORIENT-3 trial.

15-04-2021 | Oncology | News | Article

Tislelizumab offers improved outcomes over docetaxel in advanced NSCLC

The anti-PD-1 antibody tislelizumab may improve outcomes relative to docetaxel as a second- or third-line therapy for people with advanced non-small-cell lung cancer, regardless of histology or PD-L1 expression levels, researchers report.

12-04-2021 | Oncology | News | Article

​​​​​​​Neoadjuvant nivolumab addition boosts NSCLC pathologic complete response

Adding nivolumab to neoadjuvant chemotherapy significantly improves the pathologic complete response rate in patients with resectable non-small-cell lung cancer, shows the CheckMate 816 trial reported at the virtual AACR Annual Meeting 2021.

09-02-2021 | Oncology | News | Article

​​​​​​​TALENT supports low-dose CT screening for high-risk never smokers

The Taiwan Lung Cancer Screening in Never-Smoker Trial suggests that low-dose computed tomography screening may help to detect early-stage disease in never smokers at high risk for developing lung cancer.

08-02-2021 | Oncology | News | Article

ITACA pharmacogenomic adjuvant chemotherapy approach does not boost resected NSCLC outcomes

Non-small-cell lung cancer survival after complete resection was not improved by use of mRNA expression levels of two genes to guide choice of adjuvant chemotherapy, shows research reported at the IASLC 2020 World Conference on Lung Cancer.

05-02-2021 | Oncology | News | Article

Emerging options for NSCLC with rare EGFR mutations

Promising early data on several novel treatment options for non-small-cell lung cancer harboring rare EGFR alterations have been reported at the IASLC 2020 World Conference on Lung Cancer.

04-02-2021 | Oncology | News | Article

Novel immune agent shows early promise in SCLC

AMG 757, a half-life extended, bispecific T-cell engager immunotherapy directed against DLL3, has demonstrated tolerability and antitumor activity in patients with previously treated small-cell lung cancer in a phase 1 trial.

04-02-2021 | Oncology | News | Article

Real-world data support carboplatin use in malignant pleural mesothelioma

Among people receiving first-line platinum-based chemotherapy for malignant pleural mesothelioma, carboplatin is associated with similar overall survival as cisplatin, show findings presented at the IASLC 2020 World Conference on Lung Cancer.

03-02-2021 | Oncology | News | Article

LCMC3 results point to early NSCLC response with neoadjuvant atezolizumab

Two cycles of neoadjuvant atezolizumab may benefit patients with resectable non-small-cell lung cancer, indicate findings from the LCMC3 study presented at the IASLC 2020 World Conference on Lung Cancer.

03-02-2021 | Oncology | News | Article

ADAURA QoL data support osimertinib use in resected, EGFR-mutated NSCLC

Health-related quality of life is maintained during long-term treatment with adjuvant osimertinib in people with resected, EGFR-mutated non-small-cell lung cancer, research shows.

02-02-2021 | Oncology | News | Article

Antibody–drug conjugates promising in advanced NSCLC

Three early-phase studies presented at the IASLC 2020 World Conference on Lung Cancer point to the potential of antibody–drug conjugates for the treatment of different populations of patients with advanced non-small-cell lung cancer.

02-02-2021 | Oncology | News | Article

​​​​​​​Pembrolizumab–ipilimumab disappoints in PD-L1-high metastatic NSCLC

Adding ipilimumab to pembrolizumab does not boost the efficacy of the PD-1 inhibitor in untreated patients with metastatic non-small-cell lung cancer and high PD-L1 expression, but leads to worse toxicity, shows the KEYNOTE-598 trial.

01-02-2021 | Oncology | News | Article

AXL inhibitor bemcentinib deserves further attention in advanced NSCLC

The oral selective AXL inhibitor bemcentinib is well-tolerated and clinically active when combined with pembrolizumab to treat immunotherapy-naïve or refractory advanced non-small-cell lung cancer, phase 2 study data show.

01-02-2021 | Oncology | News | Article

​​​​​​​Nivolumab monotherapy supported for relapsed malignant mesothelioma

Treatment with single-agent nivolumab improves the outcomes of previously treated patients with malignant mesothelioma, suggest phase 3 study results.

Image Credits